Related Experiment Videos
[Cardiac amyloidosis. General review]
1Service de médecine interne, hôpital de la Pitié, Paris, France.
La Revue De Medecine Interne
|April 1, 1994
Summary
Cardiac amyloidosis, a common cause of non-ischemic cardiomyopathies, presents varied symptoms. Early diagnosis and recognition of cardiac amyloidosis are crucial for appropriate treatment and improved patient outcomes.
Area of Science:
- Cardiology
- Cardiovascular Diseases
- Amyloidosis
Background:
- Cardiac amyloidosis accounts for 5-10% of non-ischemic cardiomyopathies, often presenting as restrictive cardiomyopathy.
- It can mimic other heart conditions, necessitating a high index of suspicion in unexplained cardiomyopathies in adults over forty.
- Associated symptoms like peripheral neuropathy or carpal tunnel syndrome can suggest cardiac involvement, though it may also present in isolation.
Purpose of the Study:
- To highlight the diagnostic challenges and key features of cardiac amyloidosis.
- To emphasize the importance of recognizing cardiac amyloidosis for appropriate therapeutic management.
- To discuss the implications of cardiac amyloidosis on treatment strategies and prognosis.
Main Methods:
- Review of clinical presentations, diagnostic criteria, and therapeutic implications of cardiac amyloidosis.
- Analysis of paraclinical findings including echocardiography (increased myocardial echogenicity, granular sparkling appearance, left ventricular thickening) and electrocardiography (low voltage, pseudo-infarct Q waves).
- Discussion of diagnostic confirmation methods such as extra-cardiac biopsy and serum amyloid P component scintigraphy, limiting the role of endomyocardial biopsy.
Main Results:
- Cardiac amyloidosis presents diversely, often mimicking other cardiomyopathies.
- Key diagnostic indicators include specific echocardiographic and ECG findings.
- Confirmation of amyloidosis is typically achieved via non-invasive methods, guiding crucial therapeutic decisions.
Conclusions:
- Identifying cardiac amyloidosis is critical as it contraindicates certain standard cardiac medications (digitalis, calcium channel blockers, beta-blockers).
- Treatment for AL (light-chain) amyloidosis, particularly cardiac involvement, remains challenging with poor outcomes and high mortality.
- Cardiac amyloidosis carries a poor prognosis, with transplantation being a less favorable option due to disease recurrence.